Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma.
10.3349/ymj.2013.54.5.1178
- Author:
Jihye CHA
1
;
Jinsil SEONG
;
Ik Jae LEE
;
Jun Won KIM
;
Kwang Hyub HAN
Author Information
1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. jsseong@yuhs.ac
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatocellular carcinoma;
combined modality therapy;
radiotherapy;
sorafenib
- MeSH:
Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use;
Carcinoma, Hepatocellular/drug therapy/pathology/*radiotherapy;
Chemotherapy, Adjuvant;
Feasibility Studies;
Female;
Humans;
Liver Neoplasms/drug therapy/pathology/*radiotherapy;
Male;
Niacinamide/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use;
Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use;
Radiation Dosage;
Radiotherapy/adverse effects
- From:Yonsei Medical Journal
2013;54(5):1178-1185
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. MATERIALS AND METHODS: From July 2007 to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and radiotherapy. Among them, 13 patients who received radiotherapy on the bone metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the measurable metastatic lesions (measurable metastasis group). Tumor responses at 1 month after the completion of radiotherapy and overall survival were evaluated. RESULTS: The in-field response rate was 100% in the primary group and 60% in the measurable metastasis group. A decrease of more than 80% in the tumor marker alpha-fetoprotein was observed in 7 patients in the primary group (54%). Toxicities of grades 3-4 were hand-foot syndrome in 3 (17%) patients, duodenal bleeding in 1 (6%) patient, thrombocytopenia in 3 (17%) patients and elevation of aspartate transaminase in 1 (6%) patient. The median overall survival was 7.8 months (95% confidence interval, 3.0-12.6). CONCLUSION: The combined treatment of sorafenib and radiotherapy was feasible and induced substantial tumor responses in the target lesions. The results of this study emphasize the importance of individualized approach in the management of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical trial.
